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Abstract
Background
The World Health Organization (WHO) recommendation for regular tuberculosis (TB)
screening of HIV-positive individuals with Xpert MTB/RIF as the first diagnostic test has
major resource implications.
Objective
To develop a diagnostic prediction model for TB, for symptomatic adults attending for rou-
tine HIV care, to prioritise TB investigation.
Design
Cohort study exploring a TB testing algorithm.
Setting
HIV clinics, South Africa.
Participants
Representative sample of adult HIV clinic attendees; data from participants reporting1
symptom on the WHO screening tool were split 50:50 to derive, then internally validate, a
prediction model.
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Outcome
TB, defined as “confirmed” if Xpert MTB/RIF, line probe assay or M. tuberculosis culture
were positive; and “clinical” if TB treatment started without microbiological confirmation,
within six months of enrolment.
Results
Overall, 79/2602 (3.0%) participants on ART fulfilled TB case definitions, compared to 65/
906 (7.2%) pre-ART. Among 1133/3508 (32.3%) participants screening positive on the
WHO tool, 1048 met inclusion criteria for this analysis: 52/515 (10.1%) in the derivation and
58/533 (10.9%) in the validation dataset had TB. Our final model comprised ART status (on
ART > 3 months vs. pre-ART or ART < 3 months); body mass index (continuous); CD4 (con-
tinuous); number of WHO symptoms (1 vs. >1 symptom). We converted this to a clinical
score, using clinically-relevant CD4 and BMI categories. A cut-off score of3 identified
those with TB with sensitivity and specificity of 91.8% and 34.3% respectively. If investiga-
tion was prioritised for individuals with score of3, 68% (717/1048) symptomatic individuals
would be tested, among whom the prevalence of TB would be 14.1% (101/717); 32% (331/
1048) of tests would be avoided, but 3% (9/331) with TB would be missed amongst those
not tested.
Conclusion
Our clinical score may help prioritise TB investigation among symptomatic individuals.
Introduction
The World Health Organization (WHO) recommends, as part of activities to address the vast
global burden of HIV-related tuberculosis (TB), regular screening for active TB of all people
living with HIV (PLHIV) followed by Xpert MTB/RIF (Cepheid, Sunnyvale, CA) as the pri-
mary diagnostic test. [1] The recommended TB screening tool, which comprises any one of
current cough, fever, weight loss or night sweats (subsequently referred to as the WHO tool),
was developed for use in resource limited settings. [2] This simple tool, which was designed to
rule out TB prior to the provision of isoniazid preventive therapy (IPT) to PLHIV, maximises
sensitivity (78.9%) and negative predictive value (97.7% at TB prevalence of 5% in PLHIV),
but has low specificity (49.6%) and positive predictive value (8% at TB prevalence of 5% in
PLHIV). [2] South Africa, which is home to the world’s largest HIV epidemic [3] and where
62% of individuals with TB are also HIV-positive, [4] has rolled out Xpert as the initial diag-
nostic test for all individuals with symptoms suggesting TB. [5] Regular TB screening of
PLHIV with a tool that generates large numbers of patients requiring further investigation, of
whom only a small proportion will have TB, combined with a diagnostic test that is currently
far more expensive than smear microscopy, poses a huge challenge in resource constrained set-
tings. In these settings prioritising testing for those at greatest risk of TB will help preserve
resources.
Multivariable prediction models estimate the probability that an individual either has or
will develop a particular condition. These models are increasingly abundant in the literature,
with variable quality of construction as well as reporting, as highlighted by the recent TRIPOD
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statement which presents a recommended reporting framework. [6, 7] Clinical scoring algo-
rithms have been developed for PLHIV with symptoms suggestive of TB to prioritise investiga-
tion for those with greatest probability of having TB prior to antiretroviral therapy (ART)
initiation, [8] and improve case finding, [9] but these algorithms have not been validated or
applied to patients on ART.
The aim of our study was to develop a score, comprising elements readily available in pri-
mary care, to predict probability of TB in adults attending for routine HIV care screened for
TB and found WHO tool positive. This score was used to develop a simple tool to help health
care workers in resource limited settings decide whom to prioritise for TB investigation.
Methods
We used data collected for “Xpert for people attending HIV/AIDS care: test or review?”
(XPHACTOR), a prospective cohort study evaluating a risk-based algorithm to prioritise
Xpert MTB/RIF testing amongst adults attending for routine HIV care in South Africa, to
develop and validate our clinical score. Fig 1 depicts XPHACTOR study flow.
XPHACTOR study population and recruitment
We enrolled a systematic sample of adults (aged18 years) attending two hospital-based and
two community health centre (CHC) clinics in Gauteng province, South Africa, for HIV care,
irrespective of presence of symptoms suggestive of TB. Patients taking anti-tuberculosis treat-
ment within the previous 3 months were excluded. Patients were enrolled into three groups:
“on antiretroviral therapy (ART)” (currently taking or ART-experienced) group; “pre-ART”
(in HIV care but not yet taking ART) group; and “HIV Testing and Counselling (HTC)”
(newly-diagnosed HIV-positive). We recruited to the on ART group from hospital clinics
because their patient population solely comprised those ART-experienced; and pre-ART and
HTC groups were recruited from CHC clinics. At the time of the study, ART eligibility com-
prised CD4350 cells/mm3 or WHO clinical stage3.
XPHACTOR procedures
Enrolment. At enrolment, research staff administered a standardised questionnaire incor-
porating the WHO TB screening tool (any of current cough, fever, night sweats or uninten-
tional weight loss), measured height and weight, mid-upper arm circumference (MUAC), and
recorded most recent clinic CD4 cell count. Further investigation was prioritised according to
the XPHACTOR algorithm with an immediate spot sputum sample sent for Xpert MTB/RIF
for (i) all assigned “high priority” (any of: current cough, fever 3 weeks, body mass index
[BMI] <18.5 kg/m2, CD4 <100x106/l, measured weight loss10% in preceding 6 months, or
other feature raising high clinical suspicion of TB); (ii) those in pre-ART group with CD4<
200 x106/l at enrolment (iii) all in HTC group at enrolment, the latter two categories (who
were recruited for XPHACTOR substudies) because of a priori high risk of active TB. For all
other participants a spot sputum sample was frozen at -80˚C within 24 hours, for testing with
Xpert at the end of the study.
Follow-up. Participants were reviewed monthly to three months, with repeat WHO
symptom screen and a spot sputum requested for Xpert MTB/RIF if “high priority” by the
study algorithm at that visit, with the exception of those in the “on ART” group who were
asymptomatic at enrolment who were telephoned at 1 and 2 months to update locator infor-
mation but were not asked about TB symptoms. At the 3-month visit sputum (induced if nec-
essary) and blood were collected for mycobacterial culture on liquid media (Bactec MGIT 960
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Fig 1. XPHACTOR study flow. 1 High priority (any of: current cough, fever 3 weeks, body mass index (BMI) <18.5 kg/m2, CD4
<100x106/l, measured weight loss10% in preceding 6 months, or other feature raising high clinical suspicion of TB); medium
priority (any of: fever < 3 weeks, night sweats, measured weight loss <10% in preceding 6 months); low priority = no TB symptoms.
2 Samples tested with Xpert MTB/RIF at the end of the study. 3 High priority (any of: current cough, fever 3 weeks, night sweats 4
weeks, body mass index (BMI) <18.5 kg/m2, CD4 <100x106/l, measured weight loss10% in preceding 6 months, or other feature
raising high clinical suspicion of TB); medium priority (any of: fever < 3 weeks, night sweats <4 weeks, measured weight loss <10% in
preceding 6 months); low priority = no TB symptoms.
https://doi.org/10.1371/journal.pone.0181519.g001
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and 9240 systems) from all study participants. We allowed a broad window period around the
scheduled 3-month visit, till around six months, in order to maximise study follow-up.
Participants who submitted an Xpert sample were reviewed and if Xpert-positive, TB treat-
ment was initiated; if negative, further investigation in accordance with national guidelines
was facilitated (chest radiograph, sputum culture and trial of antibiotics).
Results of all investigations were fed back to clinic staff, who were responsible for manage-
ment decisions. Clinic medical records were reviewed at the end of the study to ascertain any
additional relevant investigations and/or TB diagnoses. Deaths were identified through reports
from participant-nominated contacts, clinic staff, and by accessing the Department of Home
Affairs vital statistics database using participants’ South African identification (ID) numbers.
Development and validation of the prediction model
Participants. We restricted our analysis to all XPHACTOR participants who were WHO
tool positive at enrolment and established in care (i.e. not newly testing HIV positive); and
excluded those taking isoniazid preventive therapy (IPT) at enrolment, as those on IPT were
likely to have recently undergone investigation for TB, and hence were effectively “pre-
screened” for TB.
To be deemed clinically useful a prediction model should demonstrate accurate prediction
of the outcome in data other than that in which the model was developed. We developed our
prediction model using part of our dataset, and undertook internal validation of model perfor-
mance using the remainder of the dataset. [10] Enrolment to XPHACTOR was staggered by
site, commencing with hospital clinics; hence the dataset was stratified by site and split 50:50
by median date of enrolment within site. Data from the earlier half were used to derive our
prediction model (derivation dataset), and from the latter half for validation (validation data-
set). Data were analysed using Stata 14 (Stata Corporation, College Station, TX, USA), as
detailed below.
Outcome. Our outcome was confirmed or clinical TB versus “not TB”, ascertained within
6 months of enrolment to XPHACTOR, as defined below.
“Confirmed” TB was defined as a positive result on i) Xpert MTB/RIF or ii) line probe assay
(LPA) performed on smear-positive or cultured isolate (GenoType MTBDRplus, Hain Life-
sciences) or iii) M. tuberculosis (Mtb) culture, from any sample (including stored sputum and
those requested by the health care provider) collected within six months of XPHACTOR
enrolment. Individuals who started TB treatment within six months of enrolment (including
those with treatment starts reported in the context of a separate verbal autopsy sub-study), in
the absence of microbiological confirmation, were assigned “clinical” TB. This was based on
the assumption that an HIV-positive adult with a positive bacteriological test result or starting
TB treatment within six months after enrolment likely had active TB at enrolment, supported
by data from Zimbabwe which estimated the mean duration of smear-positivity prior to TB
diagnosis amongst HIV-positive adults to be 18–33 weeks. [11]
“Not TB” was defined as fulfilling all of the following: absence of criteria for confirmed or
clinical TB; and alive at least 3 months after enrolment. Participants who did not fulfil the case
definitions for TB or “not TB” were deemed to have an unclassifiable outcome and excluded
from the analyses.
Pulmonary and extrapulmonary TB were classified in accordance with WHO definitions.
[12]
Candidate predictor selection. There is no consensus on the best method for selecting
candidate variables, but suggested approaches include using literature review, clinical knowl-
edge and studying the distribution of predictors in the study data. [6, 13, 14] It is
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recommended, to ensure predictive accuracy, that the total number of candidate predictors is
limited so that there are at least 10 outcomes for each candidate predictor studied. [6, 13] We
considered predictors from data collected at enrolment to XPHACTOR known to be associated
with prevalent and/or incident TB amongst PLHIV: age, sex, previous TB treatment, smoking,
alcohol use, history of ART, duration on ART, previous IPT, previous cotrimoxazole preventive
therapy (CPT), presence of individual WHO tool symptoms, duration of WHO tool symptoms,
BMI, MUAC, CD4 count, haemoglobin, and viral load. [15–25] History of mining, [26] health
care work, [27] and incarceration, [28] although established risk factors for TB were not consid-
ered as<10% participants fell into each category. The following variables were also excluded:
MUAC, measured weight loss, haemoglobin and viral load, due to>20% missing data; and pre-
vious IPT, as there was only one outcome amongst participants with previous IPT.
A priori we combined history of ART with duration on ART to generate “ART status” cate-
gorised as: pre-ART or on ART <3 months vs. on ART for>3 months, as amongst patients on
ART, duration of<3 months is a predictor for prevalent TB. [29] A priori we considered ART
status, CD4 cell count, and BMI for our adjusted model, and used univariable screening to
select additional candidate predictors with P-value (p)<0.25.
Model building procedures in derivation dataset. We undertook multivariable logistic
regression of candidate predictors, sequentially removing the variable with the largest Wald
p-value>0.05 (stepwise backward elimination), to generate our final model. [13] A complete-
case analysis was undertaken, excluding participants with missing information relating to any
of the candidate predictors. A model that categorised the number of WHO symptoms as 1 vs.
>1 symptom (model A) was compared with one that included individual WHO tool symp-
toms (model B), aiming to select the simplest and most practical model to implement in pri-
mary care. We also considered a model without CD4 count for settings where this might not
be easily available.
Transformations of continuous variables (BMI and CD4) were assessed using fractional
polynomials. In our final selected model we tested for interactions between remaining vari-
ables and “ART status”.
Assessing model performance in derivation dataset. We assessed model calibration, the
agreement between probability of TB predicted by the model and observed probability of TB
within quantiles of predicted risk, graphically in a calibration plot; and statistically using the
Hosmer-Lemeshow test. We assumed p<0.05 from the Hosmer-Lemeshow test as indicating
lack of model fit (poor calibration), although the test has limited statistical power to detect
poor calibration unless the sample size is large and the outcome frequent. [13] We assessed dis-
crimination, the ability of our model to differentiate patients with TB vs. those without, using
the area under the receiver-operating characteristic curve (AUROC). AUROC 0.7 to 0.79, 0.8–
0.89,0.9 are respectively considered acceptable, excellent and outstanding discrimination.
[30]
Transformation from regression model to clinical score in derivation
dataset
Continuous variables in the final model were categorised in a clinically meaningful manner
based on their functional form, and each beta coefficient from this logistic regression model
was divided by the smallest coefficient and rounded to the nearest integer to assign points to
each variable. The total number of points was summed for each participant to calculate the
clinical score.
Internal validation. We used the beta coefficients and intercept from the final regression
models (before and after categorisation of continuous variables) generated from the derivation
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dataset to calculate the risk score for each participant in our validation dataset. We converted
the risk score into predicted risk using predicted risk = 1/(1+e-risk score), [13] and assessed per-
formance of the regression model in the validation dataset by evaluating calibration and
discrimination.
Ethical approval
The study was approved by the ethics committees at the University of the Witwatersrand, Uni-
versity of Cape Town, and the London School of Hygiene & Tropical Medicine. All consenting
participants gave written consent or, for illiterate participants, witnessed verbal consent. For
illiterate participants, there was an impartial witness present during the consenting process,
who then signed the relevant witness section of the consent form. All ethics committees
approved the consent form, including the section on the use of witnessed oral consent for illit-
erate participants, at the beginning of the study. Principles expressed in the Declaration of Hel-
sinki were followed in the conduct of this research.
Results
We enrolled 3508 participants established in care (i.e. not newly testing HIV positive) to
XPHACTOR. Overall, among patients taking ART, 783/2602 (30.1%) reported one or more
symptom in the WHO tool and 79/2602 (3.0%) had TB. Among pre-ART patients 350/906
(38.6%) reported1 symptom and 65/906 (7.2%) had TB. For this analysis, 2418/3508 were
excluded because WHO tool negative (2227) or on IPT at enrolment (191), and a further 25
participants were excluded because of “unclassifiable” outcome leaving 1065 who were WHO
tool positive and eligible for our analysis (Fig 2). We undertook a complete-case analysis and
therefore excluded a further 17 participants with missing candidate predictor data (S1 Table),
leaving 1048 for our analysis.
Characteristics of study participants
Table 1 compares the characteristics of participants in the derivation and validation datasets.
There were 515 participants in the derivation dataset, enrolled between September 2012 and
September 2013, amongst whom 52 (10.1%) participants fulfilled case definitions for TB (36
confirmed, 16 clinical). In the validation dataset there were 533 participants enrolled between
May 2013 and March 2014, amongst whom 58 (10.9%) participants fulfilled case definitions
for TB (39 confirmed, 19 clinical). The proportion with pulmonary vs. extrapulmonary disease
in derivation vs. validation datasets amongst those with confirmed TB was pulmonary (35/36
vs. 37/39) and extrapulmonary (1/36 vs. 2/39); and amongst those with clinical TB was pulmo-
nary (9/16 vs. 7/19), extrapulmonary (4/16 vs. 5/19) and not recorded (3/16 vs. 7/19). [12] The
median time from enrolment to earliest of positive TB test or date TB treatment was started
amongst all participants diagnosed with TB (derivation and validation datasets combined) was
7 days (IQR 0, 63), with 90% of diagnoses made within 120 days of enrolment.
In derivation and validation datasets, median age was 41 years, 72% were in the on ART
group, most participants were female (67% vs. 71%), and the most common WHO tool
symptoms reported at enrolment were cough (59% vs. 66%) and weight loss (46% vs. 42%;
Table 1). At enrolment median CD4 was greater in derivation compared with validation data-
set (378 vs. 334 cells/mm3), and median BMI was similar (24 kg/m2). Participants in the deri-
vation dataset were more likely to report previous IPT than those in the validation dataset
(9.9% vs. 3.6%).
Clinical score for TB in HIV-positive adults in South Africa
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Development of regression model (derivation dataset)
Table 2 summarises the candidate predictors considered for model A, which categorised num-
ber of WHO symptoms reported (1 symptom vs.> 1 symptom), and the final multivariable
model. We excluded age, alcohol status and previous history of TB as p>0.25 in univariable
analysis. Our final model (model A) comprised: ART status (on ART > 3 months = 0 v pre-
ART or ART <3 months = 1); BMI (continuous, linear); CD4 (continuous, linear); number of
WHO symptoms (1 symptom = 0 v>1 symptom = 1). A linear relationship with log odds of
the outcome was found to be adequate using fractional polynomials for both BMI and CD4
count. No evidence was found for statistical interactions between ART status and CD4 count,
BMI, or number of WHO symptoms (Wald p-value0.9). This model had Hosmer-Leme-
show statistic p = 0.65 and AUROC 0.79 (95% confidence intervals [CI] 0.73–0.86) indicating
statistically adequate calibration and discrimination in the derivation dataset (Fig 3, S2 Table).
In a sensitivity analysis where we excluded all clinical TB and used a gold standard of bacterio-
logically-confirmed TB, we obtained the same final multivariable model (S3 Table).
Univariable screening to select candidate predictors may result in the rejection of important
predictors. [6, 13] When we repeated our multivariable analysis without univariable screening,
and included all candidate predictors considered for model A, using stepwise backward elimi-
nation we obtained the same final model.
Fig 2. Flow chart of study participants. 1 28/2227 TB diagnosed within six months of enrolment (25 confirmed
TB and 3 clinical TB), of whom 25 on ART and 3 pre-ART. 2 4/191 confirmed TB diagnosed within six months of
enrolment, all pre-ART BMI = body mass index. IPT = Isoniazid preventive therapy. WHO tool negative = self-
report of absence of all of: current cough, fever, night sweats and unintentional weight loss.
https://doi.org/10.1371/journal.pone.0181519.g002
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Table 1. Characteristics of participants in derivation and validation datasets.
Characteristic Derivation dataset (N = 515) Validation dataset (N = 533)
Value Value
N (%) N (%)
Demographics
Age, years Median (IQR) 41 (34,48) 41 (34,48)
Sex Female 345 (67.0%) 377 (70.7%)
Alcohol history Never 1 308 (59.8%) 353 (66.2%)
Smoking history Never 2 354 (68.7%) 383 (71.9%)
HIV/TB history
Participant category On ART 3 370 (71.8%) 381 (71.5%)
Duration since HIV diagnosed, months Median (IQR) 56 (21,95) (N = 505) 51 (6,97) (N = 531)
Duration on ART, months Median (IQR) 55 (26,85) (N = 370) 51 (28,83) (N = 381)
Ever had IPT Yes 51 (9.9%) 19 (3.6%)
Ever had CPT Yes 370 (71.8%) 355 (66.6%)
Previous TB treatment Yes 201 (39.0%) 199 (37.3%)
WHO symptoms at enrolment
Cough 304 (59.0%) 350 (65.7%)
Weight loss 235 (45.6%) 221 (41.5%)
Night sweats 131 (25.4%) 130 (24.4%)
Fever 97 (18.8%) 88 (16.5%)
Number of symptoms 1 341 (66.2%) 352 (66.0%)
2 114 (22.1%) 122 (22.9%)
3 42 (8.2%) 43 (8.1%)
4 18 (3.5%) 16 (3.0%)
Duration of WHO symptoms4, days Median (IQR) 30 (8,89) 28 (7,84)
CD4 / BMI at enrolment
CD4, cells/mm3 Median (IQR) 378 (228,543) 334 (168,559)
Range 1–1630 2–1577
Time from CD4 to enrolment, days Median (IQR) 147 (45,259) 116 (27,267) (N = 528)
BMI, kg/m2 Median (IQR) 24.0 (20.6,28.4) 24.0 (20.2,28.4)
Range 13.4–47.2 15.0–57.9
TB diagnoses over 6 months follow-up
Total 52 (10.1%) 58 (10.9%)
Confirmed TB 36 (7.0%) 39 (7.3%)
Clinical TB 16 (3.1%) 19 (3.6%)
Time from enrolment to TB diagnosis 5, days Median (IQR) 7 (0,31) (N = 52) 8 (0,83) (N = 57)
Follow up
Time from enrolment to most recent of last study / clinic 6 visit, days Median (IQR) 280 (203,350) (N = 514) 179 (133,231) (N = 532)
Alive 6 months after enrolment 7 Yes 98% (477/487) 98% (463/473)
1 compared with any alcohol in last 1 year
2 compared with ever/ex-smoker
3 compared with pre-ART group
4 duration WHO tool positive
5 defined as earliest of positive TB test or date TB treatment started
6 Most recent clinic visit at time of clinic file review
7 Amongst participants with most recent study/clinic visit <6 months from enrolment, if participant had valid South African ID number and demise not
reported by Department of home affairs / participant-nominated contacts / clinic staff within 6 months of enrolment, participant assumed to be alive at 6
months after enrolment.
IPT = isoniazid preventive therapy; CPT = cotrimoxazole preventive therapy; IQR = interquartile range
https://doi.org/10.1371/journal.pone.0181519.t001
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Internal validation of final regression model
The risk score and predicted risk were calculated for the validation dataset using model A and
showed that calibration and discrimination were adequate (Hosmer-Lemeshow p = 0.31 [S2
Table], AUROC 0.75 [95% CI 0.68–0.82]), though the calibration plot demonstrates over-pre-
diction at higher deciles of risk (Fig 3).
Alternative prediction models
S4 Table presents an alternative multivariable model developed using individual WHO tool
symptoms rather than total number of symptoms (model B). Model B comprised ART status,
BMI, cough, night sweats and unintentional weight loss. In the derivation dataset there was
evidence that presence of cough was modified by ART status (p = 0.03 for interaction term);
and the model had adequate calibration and discrimination (Hosmer-Lemeshow statistic
Table 2. Univariable and multivariable logistic regression analysis in the derivation dataset (N = 515).
Predictor Patients with
TB
Unadjusted P value Adjusted 3 P value Adjusted β
N = 52/515 odds ratio (Wald) odds ratio coefficient
n/N (%) (95% CI) (95% CI) Model A (log [adjusted OR])
(95% CI)
Age 1, years 1.00 (0.97, 1.03) 0.96
Sex Male 23/170 (13.5%) 1
Female 29/345 (8.4%) 0.59 (0.32, 1.05) 0.07
Smoking status Never smoked 28/354 (7.9%) 1
Current or ex-smoker 24/161 (14.9%) 2.04 (1.14, 3.64) 0.02
Alcohol status Current 23/207 (11.1%) 1
None in last 1 year 29/308 (9.4%) 0.83 (0.47, 1.48) 0.53
ART status On ART 3 months 24/347 (6.9%) 1 1 0
Pre-ART / ART <3
months
28/168 (16.7%) 2.69 (1.51, 4.80) 0.001 2.22 (1.17, 4.22) 0.01 0.80 (0.16, 1.44)
Ever had CPT No / don’t know 19/145 (13.1%) 1
Yes 33/370 (8.9%) 0.65 (0.36, 1.18) 0.16
Previous history of TB No 33/314 (10.5%) 1
Yes 19/201 (9.5%) 0.89 (0.49, 1.61) 0.70
Number of WHO symptoms 1 symptom 18/341 (5.3%) 1 1 0
> 1 symptom 34/174 (19.5%) 4.36 (2.38, 7.98) <0.001 3.45 (1.83, 6.49) <0.001 1.24 (0.60, 1.87)
Duration of WHO tool
symptoms
<1 week 3/97 (3.1%) 1
 1 week 49/418 (11.7%) 4.16 (1.27, 13.64) 0.02
BMI 1,2, kg/m2 0.88 (0.82, 0.94) <0.001 0.89 (0.83, 0.95) 0.001 -0.12 (-0.19, -0.05)
CD4 1,2, cells/mm3 0.997 (0.995,
0.998)
<0.001 0.998 (0.996,
0.999)
0.006 -0.002 (-0.004,
-0.0006)
1 Age, BMI and CD4 count were modelled as continuous variables
2 In the multivariable analysis BMI and CD4 count were modelled as continuous variables, a linear relationship with log odds of outcome was found to be
adequate after modelling using fractional polynomials.
3 Adjusted for all variables shown in column. 100 unit increase in CD4 corresponds to reduction in adjusted odds ratio (aOR) of TB of 0.80 (95% CI 0.68,
0.94); 5 unit increase in BMI corresponds to reduction in aOR of TB of 0.56 (95% CI 0.39, 0.79).
Intercept (log odds) for multivariable model is 0.39.
In the validation dataset the risk score was calculated using the formula: risk score = 0.39 + 0.80 (if pre-ART / ART< 3months)–(0.002 x CD4 count)–(0.12 x
BMI) + 1.24 (if > 1 symptom)
https://doi.org/10.1371/journal.pone.0181519.t002
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Fig 3. Calibration plot of final prediction model in derivation and validation datasets.
https://doi.org/10.1371/journal.pone.0181519.g003
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p = 0.81, AUROC 0.82 [95% CI 0.76–0.88]). In the validation dataset this model had poor cali-
bration (Hosmer-Lemeshow statistic p = 0.01) although discrimination was acceptable
(AUROC 0.75 [95% CI 0.69–0.82]).
We repeated our multivariable analysis using all candidate predictors considered for model
A removing CD4 count, for use in a setting where CD4 count is not easily obtainable. This model
containing ART status, BMI and number of WHO symptoms (data not shown), performed ade-
quately in the derivation dataset (Hosmer-Lemeshow statistic p = 0.54, AUROC 0.77 [95% CI
0.71–0.84]). In the validation dataset this model had poor calibration (Hosmer-Lemeshow statistic
p = 0.02) although discrimination was acceptable (AUROC 0.70 [95% CI 0.63–0.77]).
We selected model A as our final model to develop the risk score because it was simpler and
performed better in the validation dataset.
Transformation from regression model to clinical score
We used WHO BMI categorisation of<18.5 kg/m2 as underweight, 18.5–24.9 kg/m2 as nor-
mal weight, and 25 kg/m2 as overweight. CD4 count was categorised as<200 cells/mm3,
200–349 cells/mm3 and 350 cells/mm3 to reflect clinically relevant cut-offs and the skewed
CD4 count distribution amongst HIV-infected patients with TB. [31] The multivariable model
with categorisation of these continuous variables in the derivation dataset is presented in
Table 3. This model had statistically adequate discrimination in both derivation (AUROC 0.79
[95% CI 0.73, 0.86]) and validation datasets (AUROC 0.72 [95% CI 0.65, 0.79]). The Hosmer-
Lemeshow statistic p-value was 0.89 in the derivation dataset but 0.02 in the validation dataset
indicating poor calibration in the validation dataset.
The clinical score for each predictor was generated and the possible range for the total score
was 0 to 16 (Table 3).
Table 4 shows the percentage of patients diagnosed with TB at each value of clinical score in
derivation and validation datasets, and S1 Fig boxplot illustrates the distribution of clinical
score, stratified by dataset, amongst those diagnosed with TB vs. those not diagnosed with TB.
Selection of cut-off for clinical score. Fig 4 shows the performance of the clinical score at
different cut-offs, in terms of sensitivity, specificity, negative predictive value and AUROC in
the entire dataset. A cut-off of clinical score of 3 to trigger TB investigation had sensitivity
of 91.8% (95% CI 85, 96.2), specificity 34.3% (95% CI 31.3, 37.5), negative predictive value
97.3% (94.9, 98.7) and AUROC 63.1% (95% CI 60.1, 66.1). Increasing the cut-off to7, where
Table 3. Multivariable model and clinical score in the derivation dataset (N = 515).
Predictor Adjusted odds ratio (95% CI) β coefficient P value Score*
ART status On ART 3 months 1 0 0
Pre-ART / ART < 3 months 2.34 (1.22,4.46) 0.85 0.01 3
BMI, kg/m2  25 1 0 0
18.5–24.9 2.23 (1.05,4.74) 0.80 0.04 2
<18.5 6.79 (2.61,17.62) 1.91 <0.0001 6
CD4, cells/mm3  350 1 0 0
200–349 1.40 (0.63,3.11) 0.34 0.4 1
< 200 2.55 (1.23,5.30) 0.94 0.01 3
Number of WHO symptoms reported 1 symptom 1 0 0
> 1 symptom 3.59 (1.90,6.80) 1.28 <0.0001 4
Intercept (log odds) -4.23
* Each coefficient was divided by 0.335 (the smallest coefficient in our model, CD4 200–349 cells/mm3) and rounded to the nearest integer to form the score
for that predictor
https://doi.org/10.1371/journal.pone.0181519.t003
Clinical score for TB in HIV-positive adults in South Africa
PLOS ONE | https://doi.org/10.1371/journal.pone.0181519 August 3, 2017 12 / 20
sensitivity and specificity were closest offered the best discrimination (AUROC 70.1% [95% CI
65.8, 75.1]), with improvement in specificity to 73.7% (95% CI 70.7, 76.5), but sensitivity was
only 67.3% (95% CI 57.7, 75.9) although negative predictive value was maintained at 95%
(95% CI 93.2, 96.5).
We selected a cut-off of clinical score 3 to trigger TB investigation as we deemed that in
this population, in order to avoid missing TB diagnoses, maintaining a higher sensitivity was
more important than optimising discrimination. Investigating patients who had a clinical
score of 3 would have resulted in no further investigation of 30% (155/515) patients in the
derivation dataset, and missed 6% (3/52) of TB diagnoses. The same cut-off for investigation
in the validation dataset would have resulted in no further investigation of 33% (176/533)
patients and missed 10% (6/58) of TB diagnoses. Amongst the nine patients with clinical
score < 3 and TB diagnosed (4 confirmed TB, 5 clinical TB) all had had been on ART for 3
months and all reported only one symptom which was cough; median BMI was 24.3 kg/m2
(range 20.3–30.8) and median CD4 was 429 cells/mm3 (range 241–1183).
Fig 5 presents a proforma of how this scoring system, using combined data from both deri-
vation and validation datasets to demonstrate the prevalence of TB by clinical score group,
could be used in practice (combined data sets, N = 1048). If investigation was prioritised for
individuals with a score of3, 68% (717/1048) of symptomatic individuals would be tested,
among whom the prevalence of TB would be 14.1% (101/717). 32% (331/1048) of tests would
be avoided using this strategy, at the cost of missing 8% (9/110) individuals with TB or 3% (9/
331) with TB amongst those not tested.
Discussion
Our study is the first to derive and internally validate a clinical score for patients attending for
routine HIV care, both ART-experienced and pre-ART, for use as a second step after TB
Table 4. Performance of clinical score in derivation and validation datasets.
Clinical score Derivation dataset Validation dataset
Total with score Number diagnosed with TB (%) 1 Total with score Number diagnosed with TB (%) 1
0 69 1 (1.5) 90 2 (2.2)
1 24 0 32 1 (3.1)
2 62 2 (3.2) 54 3 (5.6)
3 74 3 (4.1) 50 7 (14)
4 33 3 (9.1) 37 3 (8.1)
5 52 3 (5.8) 42 2 (4.8)
6 54 4 (7.4) 54 2 (3.7)
7 41 6 (14.6) 21 4 (19.1)
8 23 6 (26.1) 33 6 (18.2)
9 21 2 (9.5) 25 2 (8.0)
10 27 7 (25.9) 34 4 (11.8)
11 7 1 (14.3) 4 1 (25)
12 18 8 (44.4) 41 18 (43.9)
13 7 4 (57.1) 6 0
14 0 2 0
16 3 2 (66.7) 8 3 (37.5)
TOTAL 515 52 533 58
1 Row percentages shown
https://doi.org/10.1371/journal.pone.0181519.t004
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screening with the WHO tool. The score is designed to assist health care workers in resource
limited settings to identify whom to prioritise for TB investigation. Our score uses elements
which should be readily available at any level of health care and is simple to use, highlighting
to less experienced clinicians those at greatest risk of TB, and providing a useful tool for other
cadres of health care worker. In our study population, not investigating those who have a clini-
cal score <3, amongst whom the prevalence of TB is 3% (9/331), would avoid investigation of
32% (331/1048) of those reporting WHO symptom(s), whilst missing only 8% (9/110) of TB
diagnoses. We hypothesise that the WHO tool positive patients with clinical score <3 who had
Fig 4. Performance of clinical score at different cut-offs offs (derivation and validation datasets combined; N = 1048).
NPV = negative predictive value. AUROC = area under the receiver-operating characteristic curve.
https://doi.org/10.1371/journal.pone.0181519.g004
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Fig 5. Clinical score and prevalence of TB.
https://doi.org/10.1371/journal.pone.0181519.g005
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TB diagnoses missed were more likely to have less advanced disease and more favourable prog-
nosis. This is suggested by their clinical characteristics (all on ART with normal weight and
CD4 count >240 cells/mm3), and consistent with findings from other studies. [32–34] In the
broader context of the original XPHACTOR study population, not investigating the 2227 who
were WHO tool negative at enrolment would have missed the 28 TB diagnoses in this group
(Fig 2). The overall risk of TB in those who were WHO tool negative or had clinical score <3
was 1% (37/2558), and the two step strategy (WHO tool followed by clinical score) would have
avoided investigating 78% (2558/3275) of clinic attendees (Fig 2). The TB diagnoses missed
using this strategy, 27% (37/138) of TB diagnoses, were mainly amongst those who were WHO
tool negative.
Our clinical scoring system compares favourably, in terms of simplicity and ability to iden-
tify patients with lowest prevalence of TB, with that derived by Balcha et al, also as a second
step after WHO symptom screen, for ART naïve patients attending for HIV care in Ethiopia.
[8] In this smaller and as yet unvalidated (internally or externally) study, amongst 569 WHO
tool positive patients, a more complex score which included Karnofsky status, MUAC, periph-
eral lymphadenopathy and anaemia, using a cut off of2 was able to avoid investigation of
45% (255/569) of whom 8% (20/255) had culture confirmed TB. Rudolf et al derived TBscore
II from a population in Bissau who were seeking care for symptoms suggestive of TB, of whom
only 164 were HIV-positive. [9] Their score is also more complex than our score, incorporat-
ing physical signs in addition to symptoms and also requires both internal and external valida-
tion.[9]
The majority of our study population were established on ART in contrast to those in the
meta-analysis which derived the WHO tool who were largely pre-ART, [2] and the populations
used to derive clinical scores by Balcha [8] and Rudolf. [9] Thus our study addresses a key
question concerning operationalisation of TB screening among the increasingly large popula-
tion of adults on ART. Our study participants were established in HIV care and thus likely had
had previous screening, which is known to reduce sensitivity of the WHO tool for bacteriologi-
cally confirmed TB, [2] as also is ART use. [35] Rangaka et al evaluated the utility of the WHO
tool to rule out TB prior to IPT in a population similar to ours, i.e. both pre-ART and on ART
although duration on ART was shorter (median 12 months), against a gold standard of cul-
ture-confirmed TB. [29] Their study suggested that amongst those on ART addition of BMI
and CD4 to the tool could be considered, but recommended sputum culture first for all prior
to IPT. [29] We ensured that in our clinical score we included BMI, CD4 and a measure of
ART status which incorporated duration on ART, and believe that our score therefore will
prove useful for all patients screened for TB during routine HIV care. Our score obviates the
need for a separate tool for those pre-ART vs. on ART, although people with newly diagnosed
HIV have such a high TB prevalence that investigation for all may be justified. [36]
In contrast with other studies deriving clinical algorithms or evaluating performance of the
WHO rule, [2, 8, 29, 33, 35] our case definition for TB included clinical TB. This reflects the
real life scenario of high TB burden resource-limited settings, and is a strength of our study.
Most of our TB diagnoses were bacteriologically-confirmed pulmonary TB, which is what the
WHO tool was largely designed to rule out prior to provision of IPT. [2] In sensitivity analysis
restricted to bacteriologically-confirmed TB we obtained the same final multivariable model
(S3 Table).
We assumed that all participants starting TB treatment or with a sample which was bacteri-
ologically confirmed collected within six months of enrolment were likely to have had active
TB at enrolment. We based this decision on data from a community survey and TB notifica-
tion data in Zimbabwe, estimating a mean duration of smear-positivity prior to TB diagnosis
amongst HIV-positive adults of 18–33 weeks. [11] In actual fact 90% of our study participants
Clinical score for TB in HIV-positive adults in South Africa
PLOS ONE | https://doi.org/10.1371/journal.pone.0181519 August 3, 2017 16 / 20
who started TB treatment commenced within four months of enrolment. In the derivation vs.
validation dataset the interquartile range for time from enrolment to TB diagnosis is shorter
(0–31 vs. 0–83 days) and this may reflect implementation of a substudy later in the course of
XPHACTOR evaluating causes for persistent TB symptoms in patients without TB diagnosis
by the 3-month visit. There were 47 participants (with 10 TB diagnoses) in this substudy in
the validation dataset compared with 7 in the prediction dataset (with 1 TB diagnosis). We
undertook the majority of our case notes reviews towards the end of the XPHACTOR study
and this is reflected in the longer duration of follow up in the derivation vs. validation dataset,
which may have resulted in ascertainment bias in terms of TB diagnoses made in the derivation
dataset, although the total number of TB diagnoses was similar in both groups. Differences
between the derivation and validation datasets represent a strength in terms of evaluating our
predictive model, as non-random splitting which reduces the similarity of the two datasets is
preferred for internal validation.[6]
We developed our score in accordance with TRIPOD recommendations [6] and internal
validation of our final multivariable model (model A) demonstrated adequate calibration and
discrimination in our validation dataset. The multivariable model resulting from our categori-
sation of BMI and CD4 in a clinically meaningful manner, also showed acceptable and clini-
cally useful discrimination in the validation dataset. Our model requires external validation in
order to confirm that it predicts well in individuals outside of our dataset [37] and, following
this, impact studies to assess patient outcomes and cost effectiveness of this strategy. [38]
Assuming external validity, our suggested threshold for investigation (clinical score3), could
be varied depending on available resources. We have suggestions for updating our prediction
model, which we were unable to evaluate due to insufficient data: MUAC, which is simpler to
measure than BMI; haemoglobin, because anaemia is a strong independent predictor of TB
amongst those poised to initiate ART; [39] and viral load. [19] Recent WHO guidelines recom-
mend ART initiation for all PLHIV at any CD4 count suggesting that in settings where viral
load monitoring can be assured that CD4 count for monitoring purposes may be reduced or
stopped. [40] CD4 count itself is not always easily available, and in these settings viral load
monitoring is also unlikely to be easily available, but given this new guidance models without
CD4 should be considered.
Strengths of our study include systematic evaluation of a representative sample of adults
attending for routine HIV care who underwent rigorous assessment for TB and longitudinal
follow-up which minimised the number of TB diagnoses missed, and model development and
validation in accordance with TRIPOD guidelines. [6]
Conclusions
We have developed and internally validated a simple clinical score comprising ART status,
BMI, CD4 count and number of WHO symptoms, for patients attending for routine HIV care
in resource limited settings. Our score is designed to identify, amongst those reporting WHO
tool symptom(s), whom should be prioritised for TB investigation. Our findings are highly rel-
evant given the national roll out of Xpert MTB/RIF in South Africa.
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